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Abstract
The cause of Huntington disease (HD) is a polyglutamine repeat expansion of more than 36 units in the huntingtin protein,
which is inversely correlated with the age at onset of the disease. However, additional genetic factors are believed to modify
the course and the age at onset of HD. Recently, we identified the V471A polymorphism in the autophagy-related gene
ATG7, a key component of the autophagy pathway that plays an important role in HD pathogenesis, to be associated with
the age at onset in a large group of European Huntington disease patients. To confirm this association in a second
independent patient cohort, we analysed the ATG7 V471A polymorphism in additional 1,464 European HD patients of the
‘‘REGISTRY’’ cohort from the European Huntington Disease Network (EHDN). In the entire REGISTRY cohort we could not
confirm a modifying effect of the ATG7 V471A polymorphism. However, analysing a modifying effect of ATG7 in these
REGISTRY patients and in patients of our previous HD cohort according to their ethnic origin, we identified a significant
effect of the ATG7 V471A polymorphism on the HD age at onset only in the Italian population (327 patients). In these Italian
patients, the polymorphism is associated with a 6-years earlier disease onset and thus seems to have an aggravating effect.
We could specify the role of ATG7 as a genetic modifier for HD particularly in the Italian population. This result affirms the
modifying influence of the autophagic pathway on the course of HD, but also suggests population-specific modifying
mechanisms in HD pathogenesis.
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Introduction
Huntington disease (HD) is one of the most common
monogenetic neurodegenerative disorders and is clinically char-
acterized by progressive development of motor disturbances as
well as cognitive and psychiatric dysfunctions mainly starting at
middle age [1]. The underlying genetic defect of HD is the
expansion of an unstable CAG repeat in the HTT gene resulting in
an elongated polyglutamine tract of the huntingtin protein (htt),
which is inversely correlated with the age-at-onset (AAO) and the
course of the disease [2–4]. The length of the polyglutamine tract
accounts for 42 to 73% of the variance in the AAO [5,6]. The
remaining variance of AAO may be due to modifier genes and
seems to be strongly heritable. However, environmental effects
such as daily activity may also modify AAO in HD patients [7]. To
date, several studies identified genetic modifiers of AAO in HD
participating in glutamatergic transmission (GRIK2, GRIN2A,
GRIN2B) [8–11], axonal trafficking (HAP1) [12], gene transcrip-
tion (TCERG1, TP53) [13,14], energy metabolism (PPARGC1A)
[15–17] or protein degradation (UCHL1, ATG7) [18–20] repre-
senting various intracellular pathways involved in pathogenic
processes of HD [21].
Recently, we found the V471A polymorphism in the autophagy-
related gene 7 (ATG7) to be associated with the AAO of HD in a
large group of more than 900 European HD patients [20]. The
gene product of ATG7 is an important part in the autophagic
machinery facilitating the degradation of long-lived proteins,
protein complexes and damaged organelles in the cell [22].
Additionally, autophagy enables the degradation of aggregate-
prone proteins such as mutant huntingtin (mhtt), which tends to
form intracellular aggregates and fails to undergo proteasomal
degradation [23,24]. Our previous study revealed a significant
effect of the ATG7 V471A polymorphism on the HD AAO
leading to an approximately 4-years-earlier onset of the first
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symptoms [20]. The rare p.471A allele might affect ATG7
function and subsequently impairs the autophagic process and the
degradation of mhtt. That ATG7 dysfunction could lead to
neurodegeneration is supported by observations in ATG7-
deficient mice, which exhibit a loss of cerebellar and cortical
neurons and the formation of ubiquitin-positive aggregates
[25,26]. On the other hand, a general induction of autophagy
results both in a reduction of soluble and aggregated mhtt and
protects against mhtt-mediated toxicity in cell, fly and mouse
models of HD [23,27,28].
In order to validate a true association of a genetic modifier with
the AAO of a disease or to facilitate a more detailed association
analysis, independent replication studies are mandatory. There-
fore, we analysed the association of the ATG7 V471A polymor-
phism with the HD AAO, which we detected in a previous study,
in a second independent population composed of more than 1,400
European HD patients and specified the modifying effect of ATG7
in different populations.
Materials and Methods
HD Patients
As the aim of this study is the analysis of the identified modifier
polymorphism ATG7 V471A in a second HD patients cohort, we
examined a patients group consisting of 1,464 unrelated European
HD patients, which were obtained by the European Huntington’s
Disease Network (EHDN) ‘‘REGISTRY’’ study prior to February,
2011 (2nd European HD cohort = EHDN REGISTRY cohort).
The EHDN REGISTRY project is a multicentre, prospective,
observational study that enrols HD expansion carriers [29]. For all
patients HD was clinically diagnosed. Motor, psychiatric and
cognitive signs were scored using the Unified Huntington’s Disease
Rating Scale (UHDRS) and AAO was estimated as the onset of
motor symptoms. The mean AAO was 43.8 (SD 12.3) and ranged
from 5 to 78 years. CAG repeat lengths in the HD gene of the
patients were mainly examined by a PCR amplification followed
by capillary electrophoresis by BioRep (Milan, Italy). The number
of the expanded CAG repeats ranged from 37 to 89 with a median
repeat number of 43. The EHDN REGISTRY cohort includes
patients from different European countries except Germany and
Italy.
Furthermore, we analysed additional patients of a 1st European
HD cohort that was already examined in a previous study [20].
This group consisted of a total of 943 European HD patients with
subgroups of 371 patients of German and 327 patients of Italian
descent. Compared to the number of investigated patients in the
previous study [20] we managed it to re-genotype 25 HD patients
of the 1st European HD cohort, which failed during the first
genotyping. Also for all these patients, HD was clinically diagnosed
and AAO was estimated as the age at which motor symptoms first
occurred. The mean AAO of the 1st European cohort patients was
45.2 (SD 13.4) and ranged from 5 to 85 years. CAG repeat lengths
of the expanded allele ranged from 39 to 90 units (median: 44). No
overlap between the 1st European HD cohort and the EHDN
REGISTRY cohort is expected.
Ethics Statement
The study was performed under a protocol approved by the
Institutional Review Board of the University of Tuebingen
Medical Faculty and the other sites of the EHDN REGISTRY
project [29]. The participants gave informed written consent
according to the International Conference on Harmonisation –
Good Clinical Practice (ICH-GCP) guidelines (http://www.ich.
org/LOB/media/MEDIA482.pdf) and according to the Declara-
tion of Helsinki.
Genotyping
As the polymorphism V471A in ATG7 was already analysed in a
large HD patient cohort in a previous study [20], we used the
same genotyping conditions as described. So genotyping of ATG7
V471A (dbSNP rs36117895) was performed by standard PCR
conditions and a following restriction analysis using 1U MboII
according to manufacturer’s instructions (New England Biolabs
Inc., Beverly, MA, USA). The nomenclature for numbering of
changes at nucleotide or amino acid level follows general rules
[30].
Statistical Analysis
For a descriptive statistical analysis allele and genotype
frequencies as well as Hardy-Weinberg distribution of the ATG7
V471A genotype was investigated by Genepop version 4.0.10
(http://genepop.curtin.edu.au/) (Table 1). Using the framework of
linear models in an analysis of variance and covariance (JMPH
Version 7.0.1, SAS Institute Inc., Cary, NC, USA), we tested the
modifying role of the ATG7 V471A polymorphism on the AAO of
HD. First, we applied a model of analysis of variance with the
ATG7 V471A polymorphism and the expanded HD allele as
independent variables and the AAO as dependent variable. The
goodness of fit was evaluated by the proportion of variation in the
AAO explained by the coefficient of determination (R2). We
obtained the best fit of our data and a minimization of the
residuals by logarithmic transformation of the AAO and the CAG
repeat number in the HTT gene. To determine the effect of the
ATG7 V471A polymorphism on AAO by an analysis of
covariance in this model, the effect of the expanded CAG allele
(HD CAG) was calculated alone, as well as with the V471A
polymorphism. A change of R2 after adding the effect of the
polymorphism indicated a relative improvement of the model and
thus identified the percentage of variance that was attributable to
the ATG7 V471A polymorphism when there was a significant P
value (P#0.05). Adjustment of multiple testing was performed
according to Bonferroni correction. Differences in the AAO of HD
Table 1. Allele and genotype frequencies of ATG7 V471A
polymorphism.
Group Allele frequency
a Genotype frequency
V A VV VA AA
EHDN REGISTRY cohort
(n = 1464)
0.961 0.039 0.947 0.053 0.000
1st European cohort
(n = 918)
0.960 0.040 0.919 0.081 0.000
Controls (n = 60) 0.967 0.033 0.933 0.067 0.000
The nomenclature for numbering of changes at nucleotide or amino acid level
follows general rules [30].
The observed genotypes did not differ from expectations under Hardy-
Weinberg equilibrium (EHDN REGISTRY cohort: P = 1.000; 1st European cohort:
P = 0.3920; controls: P = 1.000 [20]).
Genotype frequencies of Atg7 V471A in EHDN REGISTRY patients differ
significantly from the respective frequencies in HD patients of the previous
cohort (P = 0.0007).
n, number of investigated persons whose genotype could be determined.
aAllele frequency of nucleotide substitution in ATG7 is described by V ( = valine)
as major allele and A ( = alanine) as rare allele.
doi:10.1371/journal.pone.0068951.t001
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within different genotypes were determined by a two-tailed t test
(JMPH Version 7.0.1, SAS Institute Inc., Cary, NC, USA).
Results
Analysing the ATG7 V471A polymorphism in patients of the
EHDN REGISTRY [28] cohort as a second cohort of European
HD patients and comparing them with patients of a previously
examined 1st European HD cohort [20] that does not overlap with
the EHDN REGISTRY cohort, the respective alleles showed
comparable frequencies. However, the heterozygous V471A
genotype was significantly less frequent in the EHDN REGISTRY
patients than in patients of the 1st European HD cohort
(P = 0.0007) (Table 1). The expanded CAG repeat in the HTT
gene accounts for up to 66% of the variance in the AAO
(R2 = 0.6633), so that about 34% of the AAO variance has to be
determined by other factors acting as modifiers of the disease. In
contrast to our previous study where we identified the ATG7
V471A polymorphism as a modifier of HD AAO, this polymor-
phism did not exert any overall significant influence on the AAO
of the entire 1,464 EHDN REGISTRY patient cohort (Table 2).
Similar results were obtained when analysing a potential effect of
ATG7 V471A when grouping the patients according to longer and
shorter CAG repeat lengths or sex (data not shown).
In order to check whether the difference on the influence of the
ATG7 V471A polymorphism on HD AAO in the two indepen-
dent cohorts could be attributed to the origin of the patients, i.e.
the different European countries, we first analysed the impact of
the patients’ origin on their AAO. As this factor showed a highly
significant effect on the HD AAO (P,0.0001), we split the HD
patients of the EHDN REGISTRY cohort as well as the 1st
European HD cohort by ancestry and analysed the impact of the
ATG7 V471A polymorphism in these single groups. Remarkably,
the population specific analysis of an ATG7 V471A effect on HD
AAO revealed an influence of the polymorphism in addition to the
expanded HD allele only in Italian HD patients (P = 0.0119)
(Table 3). In all other examined European populations ATG7
V471A did not exert any modifying effect on the disease onset.
Also, the frequency of the heterozygous V471A genotype is
significantly higher in Italian HD patients (P,0.05) than in the
other populations, which could explain the higher heterozygosity
rate in the 1st European HD cohort of our previous study (Table 1).
The higher heterozygosity rate in Italian HD patients may have
provided sufficient power to detect the effect of the ATG7 V471A
polymorphism on the HD AAO in this population as other
analysed populations, which are comparable in size (e.g. patients
from the UK), have a significantly less amount of patients with a
heterozygous V471A genotype.
Thereby, the heterozygous V471A genotype in Italian HD
patients, who develop their first symptoms at an average age of
42.4 years, is associated with an approximately 6-years earlier
onset of the disease compared to patients homozygous for the
major allele (Table 4).
Interestingly, Italian HD patients have the oldest mean AAO
compared with patients from the other European countries
analysed in this study, which differs significantly from the mean
AAO of other European patients (Table 5). HD patients from
Denmark and France show a comparatively similar AAO
(P$0.05), which is not modified by the genotype of the Atg7
V471A polymorphism.
In the Italian population, the expanded HTT allele itself
accounts for ,46% (R2 = 0.4595) of the variance in the HD AAO,
thus allowing a broader range for an additional influence of
disease modifying factors. The ATG7 V471 polymorphism
contributes ,1.7% to the variance in the AAO representing
,3% of the variance that cannot be accounted for by the
expanded CAG repeat in the HTT gene. Interestingly, it can be
observed that both in patients of the Italian population separately
and in the whole EHDN REGISTRY cohort, the rare p.471A
allele is, with the exception of one Italian patient, only present in
patients with shorter HD alleles with #55 CAG units. Thus, the
rare p.471A allele seems to assert its modifying effect in conditions
with shorter and thus less severely affecting CAG expansions that
potentially allow a greater influence of additional modifiers.
Discussion
The present study intended to confirm the modifying effect of
the V471A polymorphism in the ATG7 gene, previously identified
in more than 900 European HD patients, in a second independent
cohort of HD patients. Instead of a replication of our previous
results in this second cohort of more than 1400 European HD
patients, which is expected to have no overlap with the patients of
our previous study, we could only detect the modifying effect of the
ATG7 V471A polymorphism in Italian HD patients of our 1st
European HD cohort. Here, the rare p.471A allele of the
polymorphism is associated with a 6-years earlier onset of the
first symptoms and thus potentially has an aggravating effect on
the disease.
With this result, we had to revise and modify the finding of our
previous study where we originally did not observe a population
specific effect of the ATG7 V471A polymorphism [20]. Re-
genotyping and addition of more patients to the analysis of the 1st
European HD cohort lead to an exclusion of the ATG7 V471A
influence on HD AAO in the German patients. This highlights the
importance that the size of a collective needs to be as big as
possible to indicate a real effect of a potential modifier.
In the analysed Italian population the modifying influence of the
ATG7 V471A polymorphism seems to be robust. It represents
about 3% of the variance in the AAO that cannot be accounted
for by the expanded CAG repeat in the HTT gene itself. The CAG
repeat determines about 46% of the whole variance in the HD
AAO and thus is in accordance with a former study that analysed
Table 2. Analysis of covariance of ATG7 in EHDN REGISTRY cohort.
Model R2 DR2 P value Least significant number of patientsa
CAGexp 0.6633 ,0.0001 6
HD CAG+Atg7 V471A 0.6633 0.0000 0.6151 22244
The level of significance was set to P = 0.05; n = 1464.
CAGexp, expanded CAG allele in huntingtin.
aMinimum number of patients, which are necessary to detect a significant effect of the analysed factor based on the respective genotypes.
doi:10.1371/journal.pone.0068951.t002
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the CAG repeat expansion in Italian HD families [31]. In
comparison with different studies, the CAG repeat in the Italian
population seems to have a relative weaker effect on the AAO
[5,6,32] and additional factors may have a greater impact on the
AAO. Depending on the population, the length of the CAG tract
accounts for up to 73% of the variance in the AAO [5,6,32]. The
remaining variance in the AAO, which is not accounted for by the
CAG repeat, is determined by other genetic and environmental
factors [33]. The impact of these additional factors also varies in
different populations. Sibling analyses revealed a contribution of
familial (genetic) factors to the HD AAO variance of up to 19% in
addition to the expanded CAG repeat [34,35], but as a genetic
factor modifies the HD AAO in one population, it can have less or
even no influence in a second population. Examples of this are
polymorphisms in the genes encoding the brain-derived neuro-
trophic factor (BDNF) [36–38], the glutamate receptor GRIK2
[8,9,39–41] or the CAG repeat length of the normal huntingtin
allele [39,42–45]. Such a population-specific effect of disease
modifying factors is also seen in other neurodegenerative diseases
like Parkinson disease (PD) or Alzheimer disease. In this regard,
BDNF shows a modifying effect in a cohort of Greek and Italian
PD patients [46,47], but not in Finnish or Swedish patients
[48,49].
The existence of population-specific effects of genetic modifiers
in HD is supported by the identification of potential chromosomal
modifier loci, which were achieved by genome wide linkage
analyses in different populations. The so called HD MAPS study,
which analysed HD patients mainly from the United States and
Canada, identified potential modifier loci on the chromosomal
regions 4p16, 6p21–23, 6q23–26 and 18q22 [50,51]. A linkage
scan in Venezuelan HD kindreds revealed loci at 2p25 and 2q35
as regions that harbour potential modifier genes, but could not
confirm locus 18q22 of the HD MAPS study [52]. The
chromosomal locus of ATG7 itself is on chromosome 3p25.3 and
thus the gene is not located in any potential modifier region
identified so far. It remains to be seen whether this region could be
identified as a linkage locus when analysing HD patients
particularly from Italy or Southern Europe.
Notably, a population specific effect of genetic modifiers on the
HD AAO has been recently reported in the Italian population for
the mitochondrial regulator PGC-1a [53]. We and others have
observed that specific PPARGC1A SNPs are associated with the
AAO of HD symptoms [15–17]. The modifying effect was mainly
observable in Italian HD patients [16,17,53] and Ramos and
coworkers suggested that this could be attributed to a population-
dependent phenotype stratification as HD patients from Italy and
Southern Europe were found to have a significantly older mean
AAO than patients from other European regions [53]. Indeed, the
Italian HD patients of the present study also showed a significantly
older AAO than patients from most other European countries,
although the sizes of the expanded CAG repeats are similar. While
HD patients from France or Spain also show the tendency, though
Table 3. Allele and genotype frequencies, Hardy-Weinberg distribution and analysis of covariance of ATG7 V471A in different
European populations.
Country Allele frequency
a Genotype frequency Hardy-Weinberg ANOVAc P-value
V A VV VA AA
Denmark (n = 101) 0.960 0.040 0.921 0.079 0.000 1.000 0.7797
France (n = 134) 0.981 0.019 0.963 0.037 0.000 1.000 0.8140
Netherlands (n = 174) 0.983 0.017 0.966 0.034 0.000 1.000 0.5537
Poland (n = 242) 0.988 0.012 0.975 0.025 0.000 1.000 0.3862
Spain (n = 168) 0.970 0.030 0.940 0.060 0.000 1.000 0.1481
UK (n = 347) 0.970 0.030 0.939 0.061 0.000 1.000 0.2611
Germany (n = 371)b 0.958 0.042 0.917 0.083 0.000 1.000 0.2988
Italy (n = 327) 0.946 0.054 0.893 0.107 0.000 0.6122 0.0238*
Populations with $100 examined HD patients are shown; n number of investigated HD patients.
aAllele frequency of nucleotide substitution in ATG7 is described by V ( = valine) as major allele and A ( = alanine) as rare allele.
bCompared to the number of investigated patients in the previous study [20] we managed it to re-genotype 25 HD patients of the 1st European HD cohort, which failed
during the first genotyping.
cAnalysis of covariance showing the effect of the ATG7 V471A polymorphism on the HD AAO in the respective population.
*significant effect, the level of significance was set to P = 0.05 and the p-value was adjusted for multiple testing according to Bonferroni correction.
doi:10.1371/journal.pone.0068951.t003
Table 4. Mean ages-at-onset of the different Atg7 genotypes in Italian HD patients.
Genotype Number of patients (n =327) Mean CAGexp (SD) Mean AAO (SD)
VV 292 45.47 (4.73) 48.12 (13.87)a
VA 35 46.31 (7.66) 42.43 (14.68)
AA – – –
CAGexp, expanded CAG repeat number in huntingtin, SD standard deviation, V major allele valine at amino acid position 471 (V471), A rare allele alanine at amino acid
position 471 (A471).
at test: patients with genotype VV differ significantly from patients with heterozygous VA genotype (P = 0.0348).
doi:10.1371/journal.pone.0068951.t004
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not significant, for a marked difference in the AAO of ATG7
V471A genotypes compared to Italian HD patients their mean
AAO is in the general AAO range of most other European
populations. A later AAO, particularly in Southern Europe, may
be due to further genetic factors, which modify the course of HD
only in Southern European populations, but are not present in HD
patients from other European regions. However, a later AAO may
also reflect population differences, which could be due to genetic
and/or environmental factors (such as method of diagnosis and
lifestyle or nutrition) as were already discussed by Ramos and
coworkers [53]. It is essential to consider such additional
environmental factors in future investigations. However, examin-
ing the Italian patients of our study as a cohesive group, the
method of diagnosing HD as well as other population specific
environmental factors should be comparable. So, it may be
possible that the ATG7 V471A polymorphism acts as a true
genetic modifier in the Italian population. Most likely it seems to
be in linkage disequilibrium with another genetic variation,
potentially located in ATG7 itself. In this regard, the current
study may also direct future modifier AAO studies in HD, such as
more population stratification, stronger selection based on a more
clearly defined AAO definition and even on selection of patients
with a specific range of expanded polyQ length.
In conclusion, the findings presented here confirm a modifying
role of the ATG7 V471A polymorphism on the AAO of HD, but
with a specific effect in the Italian population. Despite this
limitation, they provide further indication for a crucial link
between autophagy and HD pathogenesis. However, further
studies on the functional role of this potential genetic modifier are
required to establish its role in HD pathogenesis and to potentially
guide therapeutic approaches.
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heterozygous VA genotype (P = 0.0348).
bt-test: Italian patients show the oldest mean AAO, which is significantly older than the mean AAO of patients from the other presented European countries together
(Italy vs other countries: P,0.0001), but not significantly different from the mean AAO of patients from Denmark (P = 0.4728) and France (P = 0.2050).
doi:10.1371/journal.pone.0068951.t005
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